|
Germany Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Germany Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Germany .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the German pharmaceutical and healthcare industry.
Competitive intelligence, German pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the German market.
The Germany Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Germany Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the German pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Germany to test other views – a key input for successful budgeting and strategic business planning in the German pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the German Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Germany .
- Exploit The Latest Competitive German Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Germany .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Germany Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| SWOT Analysis |
| Germany Political SWOT |
| Germany Economic SWOT |
| Germany Pharmaceuticals And Healthcare Industry SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceutical Business Environment Ratings For Q209 |
| Limits of Potential Returns |
| Risks to Realisation of Returns |
Chapter - Germany – Market Summary |
| Regulatory Regime |
| Intellectual Property Developments |
| Pricing and Reimbursement Issues |
Chapter - Industry Developments |
| Healthcare Sector |
| Krankenkassen |
| Domestic Industry |
| Foreign Industry |
| Wholesale Sector |
| Retail Sector |
| Biotechnology Sector |
| Epidemiology |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: German Drug Market Expenditure Forecasts, 2004-2013 |
| Key Growth Factors – Industry |
| Table: German Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| German Economy to Be Buffeted By Global Environment |
| Table: Germany Macroeconomic Forecasts |
| Patented Market Forecast |
| Table: Germany's Patented Market Indicators, 2004-2013 |
| Table: ATC Breakdown of Prescription Drug Market, 2004-2013 (US$mn) |
| Generics Market Forecasts |
| Table: Germany's Generic Drug Market Indicators, 2004-2013 |
| OTC Market Forecast |
| Table: Germany's OTC Market Indicators, 2004-2013 (US$mn unless otherwise stated) |
| Export/Import Forecasts |
| Table: Germany's Pharmaceuticals Exports And Imports, 2004-2013 (US$mn) |
| Medical Devices Forecast |
| Medical Devices Forecast |
| Table: Leading German Medical Device Players |
| Table: Germany's Medical Device Market Indicators, 2006-2013 (US$bn unless otherwise stated) |
| Key Risks to BMI's Forecast Scenario |
Chapter - Competitive Landscape |
| Company Profiles |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Bayer |
| Boehringer Ingelheim |
Chapter - Country Snapshot: Germany Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Germany Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Germany’s drug market was worth EUR40.6bn in 2008, but is expected to drop slightly to EUR40.1bn in 2009. The market is expected to reach EUR43.9bn in 2013, a compound annual growth rate (CAGR) of 1.60%. While growth in Germany’s drug market is slowing it remains the world’s third-largest drug market and second-largest producer.
Pharmaceutical production in Germany accounts for about 10% of the world’s pharmaceuticals output by volume and 8% by value. The country is the second-largest pharmaceutical exporter after the US. The weakening of the Euro against the dollar over 2009 should help export trade.
Germany is also one of the worst-performing EU countries for supporting innovative therapies. New Molecular Entities (NMEs) launched in the past five years only account for 6.3% of the drug market, compared with 20.9% in Sweden and 14.9% in France.
Germany is the second-highest pharmaceutical spender per capita in Europe and as such the government is understandably keen to cut costs. Drug pricing and reimbursement regulation in Germany continues to be a contentious area. The introduction of a list of drugs with and without reimbursable status has been the cause of much friction between the government, the pharmaceuticals industry and doctors’ associations
Health-insurance premiums in Germany are set to rise in 2009, as pay rises of more than 10% secured by doctors take effect and increased costs of clinic services are realised.
Elsewhere, Bayer HealthCare seems to be unaffected by the current financial climate and has revealed that it is in a 'strong position' to acquire companies within the 'coming months'. Bayer said firms that make over-the-counter (OTC) medicines, manufacturers of animal health products and medical device producers were all on their radar.
Ratiopharm, Europe's leading generics brand increased its share of the German generic drug market to 20.6% from 18.7% during 2008. However, creditor banks of German billionaire Adolf Merckle, who committed suicide early in 2009, are getting ready to start the sales process for the company. Teva Pharmaceutical Industries is the likely buyer of Ratiopharm, but it is BMI's view that Israeli firm may pass on the purchase.
|
Germany Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |